PMID- 30375705
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 110
IP  - 1
DP  - 2019 Jan
TI  - Development of a T-cell receptor multimer with high avidity for detecting a 
      naturally presented tumor-associated antigen on osteosarcoma cells.
PG  - 40-51
LID - 10.1111/cas.13854 [doi]
AB  - For efficacy of peptide vaccination immunotherapy for patients with cancer, 
      endogenous expression of the target peptide/human leukocyte antigen (HLA) on 
      cancer cells is required. However, it is difficult to evaluate the expression 
      status of a peptide/HLA complex because of the lack of a soluble T-cell receptor 
      (TCR) that reacts with tumor-associated antigen (TAA) with high avidity. In the 
      present study, we developed two soluble TCR-multimers that were each directed to 
      TAA, survivin-2B (SVN-2B) and PBF in the context of HLA-A24 (SVN-2B TCR-multimer 
      and PBF TCR-multimer, respectively), from CTL clones that were established from 
      peptide-vaccinated patients. Both TCR multimers could recognize cognate 
      peptide-pulsed antigen-presenting cells, C1R-A24 cells, in a CD8-independent 
      method. Moreover, the PBF TCR-multimer successfully recognized a PBF peptide 
      naturally presented on HLA-A24(+) PBF(+) osteosarcoma cells. Taken together, the 
      results indicated that a TCR-multimer might be useful for detection of a 
      TAA-derived peptide presented by HLA in patients receiving immunotherapy.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Watanabe, Kazue
AU  - Watanabe K
AD  - Department of Cancer Immunology, Medical and Biological Laboratories Co., Ltd, 
      Ina, Japan.
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
FAU - Tsukahara, Tomohide
AU  - Tsukahara T
AUID- ORCID: 0000-0002-3678-4359
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
FAU - Toji, Shingo
AU  - Toji S
AD  - Department of Cancer Immunology, Medical and Biological Laboratories Co., Ltd, 
      Ina, Japan.
FAU - Saitoh, Shogo
AU  - Saitoh S
AD  - Department of Cancer Immunology, Medical and Biological Laboratories Co., Ltd, 
      Ina, Japan.
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
AUID- ORCID: 0000-0002-0608-3914
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
FAU - Nakatsugawa, Munehide
AU  - Nakatsugawa M
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
FAU - Kubo, Terufumi
AU  - Kubo T
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
FAU - Kanaseki, Takayuki
AU  - Kanaseki T
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
FAU - Kameshima, Hidekazu
AU  - Kameshima H
AD  - Higashi-Sapporo Hospital, Sapporo, Japan.
FAU - Terui, Takeshi
AU  - Terui T
AD  - Higashi-Sapporo Hospital, Sapporo, Japan.
FAU - Sato, Noriyuki
AU  - Sato N
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
AD  - Higashi-Sapporo Hospital, Sapporo, Japan.
FAU - Torigoe, Toshihiko
AU  - Torigoe T
AD  - Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan.
LA  - eng
GR  - 16H05451/Japan Society for the Promotion of Science Grants-in-aid for Scientific 
      Research (KAKENHI)/
GR  - 17H01540/Japan Society for the Promotion of Science Grants-in-aid for Scientific 
      Research (KAKENHI)/
GR  - 2018/the Takeda Science Foundation/
GR  - 2016/the Cell Science Research Foundation/
GR  - 2017-3/Ono Cancer Research Fund/
PT  - Journal Article
DEP - 20181201
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Survivin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*immunology/metabolism
MH  - Bone Neoplasms/*immunology/metabolism/therapy
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/immunology/metabolism
MH  - HLA-A24 Antigen/immunology/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Osteosarcoma/*immunology/metabolism/therapy
MH  - Peptides/immunology/metabolism
MH  - Receptors, Antigen, T-Cell/*immunology/metabolism
MH  - Survivin/immunology/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology/metabolism
PMC - PMC6317924
OTO - NOTNLM
OT  - HLA-A24
OT  - PBF
OT  - T-cell receptor
OT  - multimer
OT  - survivin
EDAT- 2018/10/31 06:00
MHDA- 2019/01/15 06:00
PMCR- 2019/01/01
CRDT- 2018/10/31 06:00
PHST- 2018/09/18 00:00 [received]
PHST- 2018/10/25 00:00 [revised]
PHST- 2018/10/26 00:00 [accepted]
PHST- 2018/10/31 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/10/31 06:00 [entrez]
PHST- 2019/01/01 00:00 [pmc-release]
AID - CAS13854 [pii]
AID - 10.1111/cas.13854 [doi]
PST - ppublish
SO  - Cancer Sci. 2019 Jan;110(1):40-51. doi: 10.1111/cas.13854. Epub 2018 Dec 1.